Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
- Statistically significant improvement in blood vessel volume ratio observed with seralutinib treatment
- Improvement correlated with important cardiopulmonary hemodynamic measurements
- None.
The TORREY FRI sub-study utilized novel, non-invasive CT imaging techniques from Fluidda, an innovative medical technology company, to evaluate the impact of seralutinib treatment on pulmonary arterial blood vessel volume distribution. Following 24 weeks of seralutinib treatment, a statistically significant improvement in the ratio of blood vessel volume of small to large pulmonary arteries was observed as compared to placebo, indicating that seralutinib improved pulmonary vascular abnormalities associated with PAH. This improvement correlated with important cardiopulmonary hemodynamic measurements.
Gossamer will again partner with Fluidda to evaluate FRI measurements in a sub-study of the Phase 3 PROSERA Study. If the results are confirmed in Phase 3, this non-invasive imaging modality could further support seralutinib’s anti-proliferative, anti-inflammatory, and anti-fibrotic reverse-remodeling mechanism of action.
Session and Presentation Details
Session Title: Novelties in pulmonary hypertension management (Clinical)
Date and Time: Sunday, September 10 from 9:30-10:45 AM CEST
Abstract Title: Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): results of the TORREY phase 2 imaging substudy
Presenting Author: Roham Zamanian, MD
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.
About Fluidda
Fluidda is a pioneering medical technology company specializing in Functional Respiratory Imaging solutions. Leveraging advanced imaging techniques, Fluidda's FRI technology enables non-invasive evaluation of lung function, providing valuable insights for disease assessment and treatment optimization. Fluidda is dedicated to revolutionizing respiratory care through innovation and cutting-edge medical imaging technology.
Forward Looking Statements
Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential benefits of seralutinib based on the FRI sub-study data. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer’s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; disruption to our operations from the COVID-19 pandemic, including clinical trial delays; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer’s clinical trials and preclinical studies for seralutinib; regulatory developments in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907147954/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
Source: Gossamer Bio, Inc.